title: Can radiation risks to patients be reduced without reducing radiation exposure? The status of chemical radioprotectants.
abstract: OBJECTIVE
  Medical radiation exposure has increased sixfold since 1980 and is the largest controllable source of exposure. Many efforts have been devoted to reducing dose or eliminating unnecessary examinations but with limited success. The concern regarding nuclear terrorism has focused a large amount of attention on radioprotective drugs. The purpose of this article is twofold: to review the current concepts, potential, and limitations of chemical radioprotectants in reducing stochastic and deterministic effects and to assess the potential application to diagnostic and interventional medical radiation procedures.
  
  
  CONCLUSIONS
  There are a wide variety of chemical compounds that have been studied for radioprotective effects. Although there is promising research, chemical radioprotectants have not been shown to be very effective and, with one limited exception, are not the standard of care in medicine.
authors.affiliation: Department of Radiology and Nuclear Medicine Service, New Mexico VA Health Care Services, Albuquerque, 87108, USA. fmettler@salud.unm.edu
authors.forename: Fred A
authors.initials: FA
authors.lastname: Mettler
authors.forename: David
authors.initials: D
authors.lastname: Brenner
authors.forename: C Norman
authors.initials: CN
authors.lastname: Coleman
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Kaminski
authors.forename: Ann R
authors.initials: AR
authors.lastname: Kennedy
authors.forename: Louis K
authors.initials: LK
authors.lastname: Wagner
mesh_terms: D004999:Amifostine / Q000627:therapeutic use; D003952:Diagnostic Imaging; D006801:Humans; D011835:Radiation Protection / Q000379:methods; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011837:Radiation-Protective Agents; D004999:Amifostine